Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 62Neoplasm Metastasis 10Stomach Neoplasms 9Brain Neoplasms 6Neoplasms 4HER2-positive Breast Cancer 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Lung Neoplasms 3Inflammatory Breast Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Meningeal Carcinomatosis 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Sarcoma 1Recurrence 1Pathologic Processes 1Ovarian Neoplasms 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1

Interventions

tucatinib 1trastuzumab biosimilar HLX02 1ribociclib 1pertuzumab 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Fulvestrant 1Docetaxel 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anatomic Stage II Breast Cancer AJCC v8 × Trastuzumab × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡